<DOC>
	<DOCNO>NCT00874315</DOCNO>
	<brief_summary>RATIONALE : - Relapsed refractory Neuroblastoma ( NBL ) carry poor prognosis child relapse NBL overall 3 year survival rate &lt; 10 % . Hematopoietic Stem Cell Transplant different donor ( allogeneic ) , form adoptive cellular therapy , infuse donor cell find host tumor foreign fight . After transplant , donor immune cell ( i.e . T cell , NK cell ) mediate Graft versus Tumor ( GVT ) effect may stop tumor recur . Also , reduce intensity transplant lead minimal toxicity less risk mortality heavily pre-treated NBL patient . PURPOSE : This phase II trial study well give reduce intensity ( use Fludarabine , Busulfan antithymocyte globulin ) preparative regimen follow donor stem cell transplant work treat young patient high-risk neuroblastoma relapse responded treatment .</brief_summary>
	<brief_title>Allogeneic Hematopoietic Stem Cell Transplantation Relapsed Refractory High-Risk NBL .</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine feasibility allogeneic hematopoietic stem cell transplantation reduced-intensity condition regimen comprise fludarabine phosphate , busulfan , anti-thymocyte globulin , term donor engraftment , transplant-related mortality , development acute chronic graft-vs-host disease , pediatric patient high-risk relapsed refractory neuroblastoma . Secondary - To elucidate role natural killer ( NK ) cell effectors graft-vs-tumor effect patient . - To evaluate role killer immunoglobulin-like receptor ( KIR ) mismatch donor-recipient pair outcomes patient . - To determine incidence progression-free survival 1 year post-transplantation patient . OUTLINE : This multicenter study . - Reduced-intensity conditioning regimen : Patients receive fludarabine phosphate IV 1 hour day -10 -6 , busulfan IV 2 hour day -10 ( test dose ) every 6 hour day -5 -4 , anti-thymocyte globulin IV 6-8 hour day -3 -1 day 2 . - Transplantation : Patients undergo allogeneic bone marrow G-CSF-mobilized peripheral blood stem cell transplantation day 0 . - Graft-vs-host disease ( GVHD ) prophylaxis : Patients receive cyclosporine tacrolimus IV orally begin day -2 continue day 60 day 100 , follow taper day 100 day 180 absence GVHD . Patients also receive mycophenolate mofetil IV orally day 1-30 , follow taper day 60 absence GVHD . Blood sample collect baseline day 30 , 60 , 100 correlative laboratory study . Samples analyze killer immunoglobulin-like receptor ( KIR ) mismatch genotyping immunophenotyping method ( PCR flow cytometry ) ; natural killer ( NK ) cell reconstitution flow cytometry ; NK cell function , NK cell allo-reactivity ELISPOT ELISA . After completion study treatment , patient follow periodically 1 year .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis highrisk neuroblastoma , meet one follow criterion : Refractory disease , define response , mixed response , progressive disease completion induction therapy administer accord clinical trial COGA3973 COGANBL0532 ( similar highintensity induction regimen ) Relapsed follow highdose chemoradiotherapy include autologous stem cell transplantation Achieved complete remission ( CR ) , good partial remission ( VGPR ) , partial remission ( PR ) ≤ 2 different salvage regimen , define follow : In CR treatment form salvage therapy ( e.g. , ¹³¹IMIBG , antibodybased therapy , COG NANT salvagetherapy regimen ) In VGPR PR salvage therapy No 3 sit skeletal disease determine ¹²³IMIBG scan ( regional involvement skeleton [ e.g. , pelvis , spine ] , tumor involvement &lt; 25 % site ) Bone marrow involvement ( &lt; 25 % neuroblast ) morphologic exam within past 2 week Patients soft tissue disease eligible provide exhibit either VGPR PR primary soft tissue mass sit metastatic soft tissue disease Disease status meet one follow criterion : Minimal residual disease Disease consider responsive salvage regimen Stable disease No rapidly progressive disease Donors must meet one follow criterion : Matched , relate donor ( 6/6 5/6 ) ( bone marrow donor allow ) HLAmatched unrelated donor ( 10/10 match highresolution [ HR ] type HLAA , B , C , DRB1 , DQB1 ) One allele antigenmismatched unrelated donor ( 9/10 match HR typing ) , mismatch HLAC One allele antigenmismatched unrelated donor ( 9/10 match HR typing ) , mismatch HLAA , B , DRB1 , DQB1 ( HLAC mismatch available ) PATIENT CHARACTERISTICS : Karnofsky/Lansky performance status 60100 % ANC &gt; 500/mm^3 Creatinine clearance radioisotope GFR ≥ 60 mL/min Total bilirubin &lt; 3.0 mg/dL AST ALT &lt; 5 time upper limit normal Shortening fraction ≥ 25 % ECHO OR ejection fraction &gt; 30 % MUGA FEV_1 DLCO ≥ 30 % OR normal chest xray , pulse oximetry , venous blood gas Negative pregnancy test Fertile patient must use effective contraception HIV negative No active recent ( within past 30 day ) fungal infection No proven suspect sepsis , pneumonia , meningitis unless appropriate therapeutic measure initiate control infection systemic sign longer lifethreatening No requirement oxygen ventilator support PRIOR CONCURRENT THERAPY : See Disease Characteristics Prior tandem autologous stem cell transplantation ( accord clinical trial COGANBL0532 ) allow No prior allogeneic hematopoietic stem cell transplantation More 2 month since prior autologous stem cell transplantation , myeloablative therapy , totalbody irradiation , whole abdominal radiotherapy , therapeutic ¹³¹IMIBG More 3 week since prior chemotherapy , immunotherapy ( include antiGD2 regimen ) , biologic response modifier recover More 2 week since prior local radiotherapy sit metastatic disease</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>recurrent refractory neuroblastoma</keyword>
</DOC>